AriBio's partner, Neuco United licenses AR1001 to 바카라 카지노 Pharma for commercialization in Greater China
[by Kang, In Hyo] AriBio announced on July 29 that it has selected Fosun Pharmaceutical Group (hereinafter referred to as Fosun Pharma), a leading global pharmaceutical company based in China, as its final partner for the commercialization of its oral Alzheimer's disease treatment candidate, 'AR1001 (development code),' in the Greater China region.
Neuco United Pharmaceutical (hereinafter referred to as Neuco United), the holder of exclusive sales rights for AriBio’s AR1001 in China, announced on July 28 that it has entered into an exclusive sales agreement with Shanghai 바카라 카지노 Pharma for manufacturing and commercialization of AR1001 across the Greater China region, including mainland China, Hong Kong, and Macau.
With this agreement, AriBio has formed a tripartite partnership and finalized preparations for the commercialization of AR1001 in the Greater China region. Leveraging 바카라 카지노 Pharma's robust capabilities in commercialization, regulatory affairs, and manufacturing infrastructure, the supply of AR1001 in the Chinese market is expected to expand steadily through strategic marketing initiatives moving forward.
Neuco United is collaborating with AriBio on the development of diagnostics and therapeutics for degenerative brain diseases, as well as on joint research involving artificial intelligence (AI) technologies. Headquartered in Hong Kong, Neuco United was founded by seasoned experts with extensive experience in drug development, clinical research, regulatory affairs, and global biopharmaceutical marketing. The company’s primary focus lies on R&D targeting neurodegenerative diseases, including Alzheimer's disease (AD), AI-driven new drug discovery platforms, and blood-based diagnostic technologies for AD.
In particular, Neuco United secured exclusive rights to AR1001 in China from AriBio early 2024 through a deal valued at around KRW 1.2 trillion (CNY 5.59 billion). The company is spearheading clinical and regulatory efforts in China for the ongoing global Phase 3 clinical trial of AR1001, which is currently underway in 13 countries with a total of 1,500 participants, and to date, the company has completed the enrollment of 126 patients at 25 clinical centers.
Established in 1994, 바카라 카지노 Pharma is a global pharmaceutical company headquartered in Shanghai, China. The company offers integrated solutions spanning from early-stage new drug development to commercialization in more than 50 countries worldwide. As of 2024, 바카라 카지노 Pharma reported sales of around KRW 8.3 trillion (approximately USD 5.9 billion).
바카라 카지노 Pharma is a key subsidiary of 바카라 카지노 International Group, which recorded sales of approximately KRW 37.6 trillion in 2024 and is publicly listed on the Shanghai and Hong Kong stock exchanges. The company holds a 49% stake in Sinopharm Industrial Investment, the parent company of Sinopharm, China's No. 1 pharmaceutical enterprise, thereby establishing a strategic alliance with the country’s largest pharmaceutical distribution network. 바카라 카지노 Pharma is widely recognized for its global R&D and commercialization capabilities, supported by a strong pipeline in oncology, immunology, infectious diseases, and central nervous system disorders.
Under the agreement with Neuco United, 바카라 카지노 Pharma has acquired exclusive rights for the manufacturing and commercialization of AR1001 in the Greater China region. The total contract value amounts to approximately USD 1 billion, encompassing upfront and milestone payments. In addition, the agreement also includes a separate provision for double-digit royalties (current technology fees).
Following the signing of this licensing agreement, AriBio, Neuco United, and 바카라 카지노 Pharma plan to enter into a pharmaceutical supply agreement aimed at accelerating the commercialization of AR1001 in the Chinese market. Furthermore, reflecting 바카라 카지노 Pharma Group’s strong interest in expanding commercialization rights to the ASEAN region, the three parties have agreed to initiate licensing negotiations covering the entire Southeast Asian market.
“Alzheimer’s disease remains a major neurodegenerative condition with significant unmet medical needs in China and globally,” expressed Chen Yuqing, Chairman and CEO of 바카라 카지노 Pharma. “바카라 카지노’s expertise in new drug commercialization, combined with close collaboration with AriBio and Neuco United, will accelerate the launch of AR1001 in China and offer patients with innovative treatment options.”
“It is very meaningful that 바카라 카지노 Group, a leading Chinese pharmaceutical company, taken direct initiative in the commercialization of AR1001 in the Greater China region through the final agreement,” stated Choung Jai-jun, CEO of AriBio. “바카라 카지노 Pharma’s capabilities in global new drug commercialization, combined with its position as a major shareholder of Sinopharm Group, China’s largest pharmaceutical company, will enable shared use of distribution infrastructure and strategic collaboration, which are expected to significantly facilitate the market entry and expansion of AR1001 in the future.”
“With the exclusive sales rights by country now transparently disclosed, we anticipate this will serve as a positive catalyst for key management milestones, including the upcoming merger with Solux and the successful completion of Phase 3 clinical trials,” Choung further stated.
Conversely, AriBio is currently in the process of merging with Solux, a KOSDAQ-listed company, with the merger scheduled to take effect on October 14.